All storiesEmerging therapies

Psilocybin Providers Follow Safety Guidelines, Study Finds

A recent study found that licensed psilocybin centers in Oregon generally adhere to recommended safety guidelines, offering insight into how the first regulated psilocybin programs in the U.S. operate. However, the cost of treatment could limit accessibility for many patients.

NeoMD Editors · 2026-10-13 · 02:41 AM EDT

For information, not personal medical advice. Discuss treatment decisions with a qualified clinician.

The quick read

Key takeaways

Oregon's licensed psilocybin therapy centers generally follow established safety guidelines, ensuring screening, preparation, supervision, and follow-up care during sessions.
The study highlights regulated psilocybin therapy as a promising, well-managed approach but does not assess treatment effectiveness or long-term patient outcomes.
High treatment costs at these centres may limit access for some patients, indicating potential economic barriers to broad use.

Editorial illustration for Psilocybin Providers Follow Safety Guidelines, Study Finds — AI-generated editorial illustration.

Psilocybin, a psychedelic compound found in certain mushrooms, is being explored as a potential treatment for various mental health conditions. Oregon became the first state in the U.S. to regulate psilocybin therapy, licensing centers to provide this treatment under specific safety recommendations.

Study findings on safety adherence

A new study examined Oregon's licensed psilocybin centers and found that these providers largely follow the established safety guidelines. These guidelines are intended to ensure patient safety during psilocybin sessions, covering aspects such as screening, preparation, supervision, and follow-up care.

Evidence and context

Supporting editorial illustration for Psilocybin Providers Follow Safety Guidelines, Study Finds — AI-generated editorial illustration.

This study provides practical information about how psilocybin therapy is being delivered in a regulated environment, which is important because regulation and oversight can reduce risks associated with novel treatments. The findings offer reassurance that these centers are committed to prescribed safety standards.

Limitations and uncertainties

However, this study focused on adherence to safety guidelines rather than directly measuring patient outcomes or long-term benefits. It does not confirm the effectiveness of psilocybin therapy itself, nor address potential risks or adverse effects beyond procedural safety. Additionally, the study notes that treatment costs at these centers may be high, potentially limiting access to those who cannot afford it.

Implications

While regulated psilocybin therapy offers promise, ongoing research is needed to understand its clinical benefits and risks fully. The current findings suggest a well-managed approach in Oregon's facilities but highlight economic barriers that could affect broad patient access.

Source: Medical Xpress